Key Highlights

  • Revenue for the quarter reached USD 123.0 million, compared with USD 83.5 million before, an approximate 47.2% advance (calculated), with higher test Volume and reimbursement both contributing.
  • Bottom-line income rose to USD 17.4 million from USD 5.7 million, while diluted per-share Earnings moved to USD 0.32 from USD 0.10.
  • Accessioned tests rose to about 207,000 from 163,000, and delivered, billable tests rose to roughly 206,000 from 165,000.
  • On September 30, 2026 cash and equivalents amounted to USD 561.5 million, up from USD 496.0 million at the prior year end.

Volume and Pricing Behind a 47% Revenue Gain

BillionToOne (NASDAQ:BLLN) lodged its third-quarter filing on November 4, 2026. Top-line revenue came in at USD 122.98 million, up from USD 83.52 million, and Gross Profit grew to USD 87.1 million from USD 58.4 million, implying a gross Margin near 70.9% versus 69.9% (calculated). Management connects sales to test counts and average selling prices, noting that in-network status is helping reimbursement as volume expands. Revenue from services rendered in earlier periods was USD 7.6 million compared with USD 3.7 million, which shows how reimbursement true-ups can shift a single quarter. Over 90% of nine-month revenue originated with third-party payers. The Business applies single-molecule sequencing in molecular diagnostics and sells prenatal assays such as UNITY alongside Northstar oncology tests.

Operating Spending Outpaces Profit Growth

Operating income reached USD 11.0 million, up from USD 9.6 million, even as R&D climbed to USD 20.2 million from USD 13.0 million and SG&A reached USD 55.9 million versus USD 35.8 million. Interest income contributed USD 4.9 million and a USD 1.5 million fair-value gain on a term Loan helped push Net Income to USD 17.4 million. Year to date, revenue totaled USD 340.8 million (USD 209.1 million a year earlier), Operating Income USD 34.4 million (USD 5.7 million), net income USD 43.4 million and diluted EPS USD 0.81. Stock Compensation over nine months came to USD 24.4 million, versus USD 9.6 million.

Capacity Build-Out, New Assays and Reimbursement Exposure

Launches this year include Unity Confirm in May, a circulating fetal cell confirmation assay, plus Northstar PGx, Select CH and Origin add-ons. Operating Cash Flow reached USD 37.1 million over nine months, up from USD 13.8 million, and the company borrowed USD 30 million. It has leased 229,000 square feet of laboratory space in Austin, expected to be occupied in 2027 and to process commercial samples in 2028, and it also holds a third Union City Facility for oncology. A tissue-free MRD test is expected to reach commercial availability in December 2026. Risks include dependence on payer coverage and rates, competition and the cost of building capacity ahead of demand.

Where Things Stand

Probably, but the filing shows both the strength and the cost. BillionToOne (NASDAQ:BLLN) delivered about 47% revenue growth, with test volume up about 27% (calculated), and profit expanded. Operating income nonetheless grew far more slowly than revenue as research, selling and stock compensation costs rose quickly. Gross profit and operating margins both improved over nine months, and total Assets reached USD 760.5 million. Austin expansion and a possible MRD launch in December 2026 are catalysts, while reimbursement rates and payer coverage remain the central risk, and the company drew USD 30 million of Debt while holding USD 561.5 million of cash.